Fludarabine

Generic Name: Fludarabine

Brand Names: Fludara

Drug Type: Small Molecule

Chemical Formula: C_₁₀H_₁₂FN_₅O_₄

CAS Number: 21679-14-1

Unique Ingredient Identifier: P2K93U8740

Background: Fludarabine is a chemotherapeutic agent used in the treatment of hematological malignancies. It is commonly marketed under the brand name Fludara.

Indication: For the treatment of adult patients with B-cell chronic lymphocytic leukemia (CLL) who have not responded to or whose disease has progressed during treatment with at least one standard alkylating-agent containing regimen

Associated Conditions: B-cell chronic lymphocytic leukemia/prolymphocytic leukemia/small lymphocytic lymphoma refractory, Refractory Non-Hodgkin's lymphoma

Associated Therapies: -

Clinical Trials

FCR or BR in Patients With Previously Untreated B-Cell Chronic Lymphocytic Leukemia

Phase 3

Completed

Conditions: Chronic Lymphocytic Leukemia

Interventions: Biological: Rituximab
Drug: Cyclophosphamide
Drug: Bendamustine
Drug: Fludarabine

First Posted Date: 2008-10-09

Last Posted Date: 2024-12-31

Lead Sponsor: German CLL Study Group

Target Recruit Count: 564

Registration Number: NCT00769522

Locations: 🇩🇪
Medizinische Universitaetsklinik I at the University of Cologne, Cologne, Germany

Identifying Prognostic Factors in Frontline FCR for Patients With Chronic Lymphocytic Leukemia (CLL)

Phase 2

Completed

Conditions: Chronic Lymphocytic Leukemia
Leukemia

Interventions: Drug: Fludarabine
Drug: Cyclophosphamide
Drug: Rituximab

First Posted Date: 2008-09-25

Last Posted Date: 2021-09-05

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 289

Registration Number: NCT00759798

Locations: 🇺🇸
University of Texas MD Anderson Cancer Center, Houston, Texas, United States

Chemotherapy Followed by Allogeneic Stem Cell Transplantation for Hematologic Malignancies

Not Applicable

Completed

Conditions: Hematologic Malignancies

Interventions: Procedure: Stem Cell Transplant
Drug: G-CSF
Drug: Fludarabine
Drug: cyclophosphamide
Drug: Cyclosporine
Drug: Methotrexate

First Posted Date: 2008-08-26

Last Posted Date: 2020-11-23

Lead Sponsor: Dartmouth-Hitchcock Medical Center

Target Recruit Count: 18

Registration Number: NCT00741455

Locations: 🇺🇸
Dartmouth-Hitchcock Medical Center, Lebanon, New Hampshire, United States

Stem Cell Transplant in Treating Patients With Hematological Cancer or Other Disorders

Phase 2

Conditions: Graft Versus Host Disease
Leukemia
Lymphoma
Multiple Myeloma and Plasma Cell Neoplasm
Precancerous Condition

First Posted Date: 2008-08-25

Last Posted Date: 2010-01-28

Lead Sponsor: Institut Paoli-Calmettes

Target Recruit Count: 50

Registration Number: NCT00740467

Locations: 🇫🇷
Marseille Institute of Cancer - Institut J. Paoli and I. Calmettes, Marseille, France

Lenalidomide Dose Escalation Combined With Rituximab/Fludarabine in Untreated CLL

Phase 1

Completed

Conditions: Leukemia, Lymphocytic, Chronic, B-Cell

Interventions: Drug: Lenalidomide
Drug: Fludarabine
Biological: Rituximab

First Posted Date: 2008-08-21

Last Posted Date: 2013-08-30

Lead Sponsor: Arbeitsgemeinschaft medikamentoese Tumortherapie

Target Recruit Count: 45

Registration Number: NCT00738829

Locations: 🇦🇹
Universitaetsklinik f. Innere Medizin III, Salzburg, Austria
🇦🇹
Klinikum Wels-Grieskirchen GmbH, Wels, Austria
🇦🇹
Medizinische Universitaet Innsbruck, Abtlg. f. Haematologie und Onkologie, Innsbruck, Tirol, Austria

and more 4 locations

Lenalidomide, Fludarabine & Cyclophosphamide in Advanced Chronic Lymphocytic Leukemia Not Responding to Therapy

Phase 1

Completed

Conditions: Chronic Lymphocytic Leukemia

First Posted Date: 2008-08-04

Last Posted Date: 2019-01-22

Lead Sponsor: Gruppo Italiano Malattie EMatologiche dell'Adulto

Target Recruit Count: 42

Registration Number: NCT00727415

Locations: 🇮🇹
Istituto Scientifico Romagnoli per lo Studio e la Cura dei Tumori- IRST, Meldola, Italy
🇮🇹
Unità Operativa Ematologia 1 - Università degli Studi di Bari, Bari, Italy
🇮🇹
Istituto di Ematologia e Oncologia Medica "Lorenzo e A. Seragnoli" - Università degli Studi di Bologna - Policlinico S. Orsola - Malpighi, Bologna, Italy

and more 20 locations

Donor Umbilical Cord Blood Transplant in Treating Patients With Hematologic Cancer

Phase 2

Completed

Conditions: Recurrent Plasma Cell Myeloma
Refractory Chronic Myelogenous Leukemia
Refractory Follicular Lymphoma
Recurrent Chronic Lymphocytic Leukemia
Recurrent Mantle Cell Lymphoma
Recurrent Marginal Zone Lymphoma
Recurrent T-Cell Non-Hodgkin Lymphoma
Recurrent Lymphoplasmacytic Lymphoma
Myelodysplastic Syndrome
Myeloproliferative Neoplasm

Interventions: Procedure: Allogeneic Hematopoietic Stem Cell Transplantation
Drug: Cyclophosphamide
Drug: Cyclosporine
Drug: Fludarabine Phosphate
Other: Laboratory Biomarker Analysis
Drug: Mycophenolate Mofetil
Radiation: Total-Body Irradiation
Procedure: Umbilical Cord Blood Transplantation

First Posted Date: 2008-07-28

Last Posted Date: 2019-12-27

Lead Sponsor: Fred Hutchinson Cancer Center

Target Recruit Count: 73

Registration Number: NCT00723099

Locations: 🇺🇸
University of Colorado Hospital, Aurora, Colorado, United States
🇺🇸
Froedtert and the Medical College of Wisconsin, Milwaukee, Wisconsin, United States
🇺🇸
Colorado Blood Cancer Institute, Denver, Colorado, United States

and more 3 locations

Donor Umbilical Cord Blood Transplant in Treating Patients With Advanced Hematological Cancer or Other Disease

Phase 2

Terminated

Conditions: Leukemia
Lymphoma
Multiple Myeloma and Plasma Cell Neoplasm
Myelodysplastic Syndromes
Myelodysplastic/Myeloproliferative Diseases

Interventions: Biological: anti-thymocyte globulin
Drug: cyclophosphamide
Drug: cyclosporine
Drug: fludarabine phosphate
Drug: mycophenolate mofetil
Procedure: umbilical cord blood transplantation
Radiation: total body irradiation

First Posted Date: 2008-07-22

Last Posted Date: 2017-06-14

Lead Sponsor: Fred Hutchinson Cancer Center

Target Recruit Count: 13

Registration Number: NCT00719849

Locations: 🇺🇸
Fred Hutchinson Cancer Research Center, Seattle, Washington, United States

Umbilical Cord Blood Transplant, Cyclophosphamide, Fludarabine, and Total-Body Irradiation in Treating Patients With Hematologic Disease

Phase 2

Active, not recruiting

Conditions: Acute Biphenotypic Leukemia
Chronic Myelogenous Leukemia, BCR-ABL1 Positive
Chronic Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive
Acute Myeloid Leukemia
Chronic Lymphocytic Leukemia
Lymphoplasmacytic Lymphoma
Mantle Cell Lymphoma
Myelodysplastic Syndrome
Non-Hodgkin Lymphoma
Acute Lymphoblastic Leukemia

Interventions: Drug: Cyclophosphamide
Drug: Cyclosporine
Procedure: Double-Unit Umbilical Cord Blood Transplantation
Drug: Fludarabine
Other: Laboratory Biomarker Analysis
Drug: Mycophenolate Mofetil
Radiation: Total-Body Irradiation
Procedure: Umbilical Cord Blood Transplantation
Drug: Thiotepa

First Posted Date: 2008-07-22

Last Posted Date: 2024-01-05

Lead Sponsor: Fred Hutchinson Cancer Center

Target Recruit Count: 135

Registration Number: NCT00719888

Locations: 🇺🇸
University of Colorado Hospital, Aurora, Colorado, United States
🇺🇸
VA Puget Sound Health Care System, Seattle, Washington, United States
🇺🇸
Fred Hutch/University of Washington Cancer Consortium, Seattle, Washington, United States

Non-Myeloablative Allogeneic HSCT From HLA Matched Related or Unrelated Donors for the Treatment of Low Grade B Cell Malignancies

Phase 2

Terminated

Conditions: Multiple Myeloma
Waldenstroms
CLL / SLL
Non Hodgkin's Lymphoma
Mantle Cell Lymphoma

Interventions: Drug: Fludarabine
Radiation: Total Body Irradiation
Other: Infusion of Stem Cells

First Posted Date: 2008-07-14

Last Posted Date: 2017-07-24

Lead Sponsor: University of Alabama at Birmingham

Target Recruit Count: 5

Registration Number: NCT00714259

Locations: 🇺🇸
University of Alabama in Birmingham BMT/CT Program Outpatient Clinic, Birmingham, Alabama, United States

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

Home Terms & Conditions Privacy Policy